CME Corner

This activity has expired. CME/CE credit is no longer available and the following content may not be available or may not be up-to-date. For a list of current activities that offer CME/CE credit, click here.

Program Detail

Release Date: November-04-13
Credit Expiration Date: November-04-14


Anthony Lembo, MD
Associate Professor of Medicine
Department of Medicine
Division of Gastroenterology
Beth Israel Deaconess Medical Center
Harvard Medical School
Boston, MA

Lawrence Schiller, MD, FACP, FACG
Professor of Medicine
Texas A&M College of Medicine
Baylor University Medical Center Campus
Dallas, TX

CCME Reviewer
David A. Greenwald, MD
Professor of Clinical Medicine
Department of Medicine (Gastroenterology & Liver Diseases)
Montefiore Medical Center
Bronx, NY

Credit Hours

Physicians: 1.0 AMA PRA Category 1 CreditTM


Online Presentation

Program Description


Irritable bowel syndrome with constipation (IBS-C) and chronic constipation (CC) are two of the most common functional disorders of the gut. Although not life-threatening, IBS-C and CC can profoundly and negatively affect patients' quality of life and are associated with a significant economic burden related to direct and indirect annual health-care costs.

A variety of treatments are available for both of these conditions, including pharmacological and nonpharmacological approaches. The most important factor in treating patients with IBS-C and CC is accurately diagnosing the cause of the disorder.

Because many clinicians lack confidence in accurately diagnosing IBS-C and CC, this activity will examine the pathophysiology and symptoms of these different conditions. Because patients with IBS-C or CC often continue to experience symptoms despite receiving treatment for their condition, the safety and efficacy of traditional and emerging therapies for IBS-C and CC are also summarized.

The goal of this continuing education activity is to expand the ability of gastroenterologists, primary care providers, and other clinicians to diagnose, treat and manage IBS-C and CC, ultimately resulting in improved outcomes for their patients.

Program Developer/Facilitator

This activity is jointly provided by Albert Einstein College of Medicine and Montefiore Medical Center, and MCM Education.

Target Audience

This program has been developed specifically for gastroenterologists, primary care and internal medicine physicians, and other clinicians interested and involved in the treatment of patients with IBS-C/CC.

Learning Objectives

Upon completion of this educational activity, the participant should be able to:

  1. Delineate the differences between symptoms of IBS-C and CC
  2. Outline diagnostic criteria for IBS-C
  3. Discuss appropriate questions that may facilitate good communication with the patient
  4. Review effective evidence-based treatment strategies for IBS-C and treatment-refractory IBS-C
  5. Discuss and compare current and emerging therapeutic options for IBS-C


The “Conflict of Interest Disclosure Policy” of Albert Einstein College of Medicine requires that faculty participating in any CME activity and anyone in a position to influence content disclose to the audience any relationship(s) with a pharmaceutical or equipment company. Any presenter whose disclosed relationships prove to create a conflict of interest, with regard to their contribution to the activity, will not be permitted to present.

The Albert Einstein College of Medicine also requires that faculty participating in any CME activity and anyone in a position to influence content disclose to the audience when discussing any unlabeled or investigational use of any commercial product, or device, not yet approved for use in the United States.

Contributors whose COIs are irresolvable are not permitted to participate in Einstein CME activities.

Dr. Lembo discloses that he has served as a consultant for Ironwood Pharmaceuticals, Forest Pharmaceuticals, Inc., Salix Pharmaceuticals, and Prometheus Labs.

Dr. Schiller discloses that he has served as a consultant for Ironwood Pharmaceuticals and Synergy Pharmaceuticals Inc., and on speakers' bureaus for Santarus, Inc., Abbott & AbbVie, Forest Laboratories, Inc., Ironwood Pharmaceuticals, and Takeda.

Albert Einstein College of Medicine:
The Staff of CCME of Albert Einstein College of Medicine have no disclosures to report with any commercial interests relative to this CME activity.

David A. Greenwald, MD, has no relevant financial conflicts to disclose.

Kathleen Hines has no relevant financial conflicts to disclose.

Credit Statements

ACCME ACCREDITATION STATEMENT: This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through joint sponsorship of Albert Einstein College of Medicine of Yeshiva University, Montefiore Medical Center, and MCM Education. Albert Einstein College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

ACCME CREDIT DESIGNATION STATEMENT: Albert Einstein College of Medicine of Yeshiva University designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Commercial Support Statements

Supported by an independent educational grant from Forest Laboratories, Inc.

Certificate Fee



©2013, Albert Einstein College of Medicine of Yeshiva University and MCM Education. The opinions expressed in this educational activity are those of the faculty and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, Albert Einstein College of Medicine & Montefiore Medical Center, Center for Continuing Medical Education, or Forest Laboratories, Inc. Any medications, diagnostic procedures, or treatments discussed by the presenters should not be used by clinicians or other health care professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.

By clicking START PROGRAM I acknowledge that I have read the CME/CE information above.

Main Menu